Literature DB >> 23828305

Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study.

Edward T H Fysh1, Alain Tremblay2, David Feller-Kopman3, Eleanor K Mishra4, Mark Slade5, Luke Garske6, Amelia O Clive7, Carla Lamb8, Rogier Boshuizen9, Benjamin J Ng10, Andrew W Rosenstengel11, Lonny Yarmus3, Najib M Rahman4, Nick A Maskell7, Y C Gary Lee12.   

Abstract

BACKGROUND: Indwelling pleural catheters (IPCs) offer effective control of malignant pleural effusions (MPEs). IPC-related infection is uncommon but remains a major concern. Individual IPC centers see few infections, and previous reports lack sufficient numbers and detail. This study combined the experience of 11 centers from North America, Europe, and Australia to describe the incidence, microbiology, management, and clinical outcomes of IPC-related pleural infection.
METHODS: This was a multicenter retrospective review of 1,021 patients with IPCs. All had confirmed MPE.
RESULTS: Only 50 patients (4.9%) developed an IPC-related pleural infection; most (94%) were successfully controlled with antibiotics (62% IV). One death (2%) directly resulted from the infection, whereas two patients (4%) had ongoing infectious symptoms when they died of cancer progression. Staphylococcus aureus was the causative organism in 48% of cases. Infections from gram-negative organisms were associated with an increased need for continuous antibiotics or death (60% vs 15% in gram-positive and 25% mixed infections, P = .02). The infections in the majority (54%) of cases were managed successfully without removing the IPC. Postinfection pleurodesis developed in 31 patients (62%), especially those infected with staphylococci (79% vs 45% with nonstaphylococcal infections, P = .04).
CONCLUSIONS: The incidence of IPC-related pleural infection was low. The overall mortality risk from pleural infection in patients treated with IPC was only 0.29%. Antibiotics should cover S aureus and gram-negative organisms until microbiology is confirmed. Postinfection pleurodesis is common and often allows removal of IPC. Heterogeneity in management is common, and future studies to define the optimal treatment strategies are needed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23828305     DOI: 10.1378/chest.12-3103

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

Review 1.  Minimally invasive palliative interventions in advanced lung cancer.

Authors:  Christopher Mallow; Margaret Hayes; Roy Semaan; Thomas Smith; Russell Hales; Roy Brower; Lonny Yarmus
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

2.  Tunneled pleural catheter use for pleural palliation does not increase infection rate in patients with treatment-related immunosuppression.

Authors:  Candice L Wilshire; Christopher R Gilbert; Brian E Louie; Ralph W Aye; Alexander S Farivar; Eric Vallières; Jed A Gorden
Journal:  Support Care Cancer       Date:  2017-11-29       Impact factor: 3.603

3.  Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.

Authors:  Christopher Kniese; Khalil Diab; Marwan Ghabril; Gabriel Bosslet
Journal:  Chest       Date:  2018-07-07       Impact factor: 9.410

4.  Open window thoracostomy as an alternative approach to secondarily infected malignant pleural effusion and failure of intrapleural catheter drainage: a case report.

Authors:  Anthony M Villano; Raul Caso; M Blair Marshall
Journal:  AME Case Rep       Date:  2018-04-13

5.  The Use of Indwelling Tunneled Pleural Catheters for Recurrent Pleural Effusions in Patients With Hematologic Malignancies: A Multicenter Study.

Authors:  Christopher R Gilbert; Hans J Lee; Joseph H Skalski; Fabien Maldonado; Momen Wahidi; Philip J Choi; Jamie Bessich; Daniel Sterman; A Christine Argento; Samira Shojaee; Jed A Gorden; Candice L Wilshire; David Feller-Kopman; Ricardo Ortiz; Bareng Aletta Sanny Nonyane; Lonny Yarmus
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

6.  Patient evaluation for rapid pleurodesis of malignant pleural effusions.

Authors:  Rebecca Krochmal; Chakravarthy Reddy; Lonny Yarmus; Neeraj R Desai; David Feller-Kopman; Hans J Lee
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

7.  Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.

Authors:  Rajesh Thomas; Edward T H Fysh; Nicola A Smith; Pyng Lee; Benjamin C H Kwan; Elaine Yap; Fiona C Horwood; Francesco Piccolo; David C L Lam; Luke A Garske; Ranjan Shrestha; Christopher Kosky; Catherine A Read; Kevin Murray; Y C Gary Lee
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

Review 8.  Current best practice in the evaluation and management of malignant pleural effusions.

Authors:  Steven Walker; Anna C Bibby; Nick A Maskell
Journal:  Ther Adv Respir Dis       Date:  2016-10-24       Impact factor: 4.031

Review 9.  Contemporary approach to the patient with malignant pleural effusion complicating lung cancer.

Authors:  Oleg Epelbaum; Najib M Rahman
Journal:  Ann Transl Med       Date:  2019-08

Review 10.  Diagnosis and management of malignant pleural effusions: state of the art in 2017.

Authors:  Neeraj R Desai; Hans J Lee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.